|
Ventrus Biosciences is a fast-growing privately held specialty pharmaceutical company focused on the late-stage development and commercialization of gastrointestinal (GI) products. Strategically, Ventrus Biosciences concentrates on licensing late-stage GI products in areas of unmet need. The development strategy for each asset is based on the most efficient path to regulatory approval, with the full potential of each asset achieved by means of additional postmarketing indications.
The Ventrus Biosciences executive team has extensive experience in developing and commercializing pharmaceutical products in specialty markets. President and CEO Thomas Rowland has over 18 years of commercial experience in specialty markets, including nine years in gastroenterology. Senior Vice President and Chief Medical Officer Terrance Coyne, MD, has over 20 years of VP-level experience in clinical development and has been involved with at least 13 submissions of new drug applications (NDAs). Vice President of Clinical Operations John Dietrich, PhD, has over 16 years of VP-level experience in preclinical and clinical development, has managed 12 clinical trials, and has been involved with three NDA submissions.
The Ventrus Biosciences Executive Team
Thomas Rowland
President, Chief Executive Officer
Mr. Rowland joined Ventrus Biosciences in April 2007. Before joining Ventrus, Mr. Rowland was founder and principal of his own consulting firm, which served various pharmaceutical and biotechnology companies in the areas of business development, marketing, and launch preparation. Mr. Rowland started consulting after serving as vice president of the gastroenterology and women’s health business unit at Solvay Pharmaceuticals, where he oversaw all commercial operations for this $250-million and 250-person unit. Before being named vice president at Solvay, Rowland successfully led the turnaround of the company’s gastrointestinal franchise, returning it to positive sales growth and achieving record profitability. Mr. Rowland’s initial work in the gastroenterology therapeutic area began when he joined Scandipharm, as director of marketing to assist in that company’s turnaround, which resulted in the sale of the company to Axcan Pharmaceuticals. Mr. Rowland started his career at UCB Pharma, where he spent over 8 years in various positions of increasing responsibility, including sales, market research, and product management. Throughout his career, Mr. Rowland has participated in numerous successful new-product and line-extension launches. In addition, in senior management roles, he has contributed to several product, franchise, and company turnarounds. Mr. Rowland earned his BS in finance from Metropolitan State University in Denver, Colorado.
Terrance Coyne, MD
Senior Vice President, Chief Medical Officer
Dr. Coyne joined Ventrus Biosciences in June 2007. With more than 30 years of experience in the pharmaceutical and biotechnology industries, Dr. Coyne has served in progressively increasing senior executive roles in medical affairs and clinical research and development. Dr. Coyne has led a division of a Fortune 50 company, served as president and CEO of a start-up company, and served as managing director of a small life-sciences investment banking firm. He has directed or been associated with the development of – and ultimately with the NDA filing (or equivalent) for – 13 products in the United States, Canada, Europe, and Australia for 3M Pharmaceuticals, 3M Health Care Specialties Division, Abbott Laboratories, Celltech-Medeva, Encysive Pharmaceuticals, Ferghana Partners, Genetix Pharmaceuticals, Medeva, and Metaphore Pharmaceuticals. The product categories ranged from analgesic, antiallergic, antiarthritic, cardiovascular, CNS, and pulmonary agents to antiinfectives and vaccines. Dr. Coyne received his undergraduate and medical degrees from the University of Wisconsin and entered private practice in family medicine after postgraduate training before entering the pharmaceutical industry.
John Dietrich, PhD
Vice President, Clinical Operations
Dr. Dietrich joined Ventrus Biosciences in April 2007. From 2000 to 2007, Dr. Dietrich was vice president of research and development at VIVUS, Inc., a biopharmaceutical company involved with the development of products for sexual dysfunction. At VIVUS, Dr. Dietrich was the primary liaison with a Japanese pharmaceutical company regarding a licensed product. From 1999 to 2000, Dr. Dietrich was vice president of research and development at Cellegy Pharmaceuticals. From 1991 to 1999, Dr. Dietrich was senior vice president of research and development at Allelix Biopharmaceuticals. In this position, he was responsible for all aspects of drug discovery and development, including regulatory affairs. At Allelix, Dr. Dietrich was the primary liaison with Astra in a joint development program for a peptide for osteoporosis. Before joining Allelix, he was vice president of research at Chemex and director of endocrinology at Revlon Health Care. Dr. Dietrich received his PhD in pharmacology from the University of North Carolina at Chapel Hill..
|
|
